Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 761

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 761
---
000, in addition to percentage royalty payments ranging from 5% to 15% which may decrease or increase up to 30% if the Company challenges the validity of the patents under the agreement, depending on the result of such challenge. Further, pursuant to the Aexon Agreement, the Company has agreed to pay Aexon a percentage of license fees, milestones and royalties received from sublicensees, ranging between 5% Annex F-27 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS and 15% which may decrease or increase up to 30% if the Company challenges the validity of the patents under the agreement, depending on the result of such challenge. For the year ended December 31, 2024, the Company recorded fees to Aexon of $ 170,000which is included in research and development expenses on the statement of operating and comprehensive loss. In October 2024, the Company entered into a consulting agreement with Ms. Nicole Fernandez -McGovern, the Company’s current Chief Financial Officer, pursuant to which the Company agreed to pay Mr. Fernandez -McGoverna monthly retainer for her services of $ 18,000per month. For the year ended December 31, 2024, the Company recorded fees to Ms. Fernandez -McGovernof $ 54,316which is included in general and administrative expenses on the statement of operating and comprehensive loss. Note 13 Subsequent Events: Management has evaluated subsequent events that have occurred through the date these consolidated financial statements were issued. In January 2025, the Company completed the initial closing of $ 500,000of the previously announced $ 1million financing between the Company and an accredited investor under a securities purchase agreement dated December 4, 2024, with the approval of certain items in Company’s extraordinary general meeting on January 7, 2025. As of May 15, 2025, the conditions for the second tranche were not met and did not occur. On January 30, 2025, the Merger Agreement was amended such that it includes the right of the Company and Kadimastem to terminate the Merger Agreement if the Closing shall not have occurred on or before April 30, 2025, which outside date can be further extended by mutual agreement. Further, the amendment included an additional provision providing that any shareholder receiving common shares in excess of a 9.99% beneficial ownership limitation as